In a quiet room in a clinic or spa, a patient might hear the gentle wash of a forest stream or the resonant hum of a Tibetan singing bowl. The sound isn't coming from a speaker in the corner, but seems to originate from the space around them, a three-dimensional audio field designed to lower cortisol and ease anxiety. This is the clinical environment Spherison, an Italian neuroscience startup, is trying to commercialize. Its bet is that a patented audio technology, delivered through open-air hardware, can carve out a space between consumer wellness gadgets and regulated medical devices [Startupbusiness, October 2026].
As of October 2026, the company reported approximately 100 of its devices installed across clinics, hospitals, wellness centers, and spas in Italy and Switzerland [Startupbusiness, October 2026]. The seed-stage startup has raised a total of roughly €650,000, with a €500,000 SAFE round opened in late 2026 [Startupbusiness, October 2026]. Its path forward hinges on proving that what it calls "hexa-aural" or Sound 6D technology can deliver measurable, repeatable patient benefits in a field crowded with unsubstantiated claims.
The bet on open-air binaural beats
Spherison’s core technology is an evolution of binaural beats, an auditory illusion where slightly different frequencies played into each ear are perceived by the brain as a single, low-frequency pulse. The effect, long studied for its potential to influence brainwave states, has traditionally required headphones. Spherison’s patented twist is to recreate a similar effect using an open-air audio system, which the company brands as hexa-aural or Sound 6D [Startupbusiness, October 2026].
The commercial strategy is to avoid the crowded consumer headphone market entirely. Instead, Spherison positions its hardware as a sound-wellness station for professional settings: beauty farms, luxury hotel spas, wellness centers, and crucially, clinical environments [LinkedIn, Unknown]. The company suggests the immersive sound stimulation could serve as a "feasible and well-tolerated nonpharmacological intervention for anxiety symptoms" [ResearchGate, Unknown]. This positioning allows it to target a B2B customer with a budget for therapeutic equipment, while building a use case that could, in theory, support future clinical validation.
A founding team of legendary pedigrees
What makes Spherison an outlier in the neuro-wellness space is the pedigree of its founding team. The co-founders bring deep, if unconventional, expertise to the problem of sound and consciousness.
- Federico Faggin, Physicist and Inventor. Often called the father of the microprocessor, Faggin was the project leader and designer of the Intel 4004. He later founded Zilog and co-founded Synaptics, the company behind the modern touchpad [Forbes, July 1997] [The New York Times, June 1990]. In recent decades, his focus has shifted toward the scientific study of consciousness through his foundation [Apple Podcasts, Unknown]. For Spherison, he provided €150,000 in pre-seed funding and advised on initial research and device development [Startupbusiness, October 2026].
- Pierpaolo Guerrini, Sound Engineer. A three-time Grammy-nominated engineer who has worked extensively with Andrea Bocelli, Guerrini is credited as a co-creator of the hexa-aural technology [Startupbusiness, October 2026]. His role bridges the gap between acoustic engineering and therapeutic application.
- Lando Santerini, Entrepreneur and Musician. The third co-founder and co-creator, Santerini adds entrepreneurial and creative direction to the venture [Startupbusiness, October 2026].
The project was incubated for about a year by 86k, a corporate venture builder involved in governance and operations [Startupbusiness, October 2026]. Business adviser Alberto Baccari is also listed as being at the company's helm [Startupbusiness, Unknown].
| Role | Name | Key Background |
|---|---|---|
| Co-founder, Investor | Federico Faggin | Inventor of the Intel 4004 microprocessor; founder of Zilog and Synaptics. |
| Co-founder | Pierpaolo Guerrini | Three-time Grammy-nominated sound engineer for Andrea Bocelli. |
| Co-founder | Lando Santerini | Entrepreneur and musician. |
| Incubator | 86k | Corporate venture builder that incubated the project. |
| Business Adviser | Alberto Baccari | Listed as being "at the helm" of Spherison [Startupbusiness, Unknown]. |
Traction in a niche channel
The company’s reported installation base of about 100 devices offers a snapshot of early, niche traction. Placing hardware in clinics and high-end spas represents a classic wedge strategy: start in environments where ambient, therapeutic sound is already a valued part of the service offering. Success in these venues provides real-world proof points, recurring revenue from site licenses or subscriptions, and a controlled setting to gather user feedback and biometric data.
The €500,000 SAFE note opened in October 2026 is intended to convert at a future financing round planned for 2027 [Startupbusiness, October 2026]. This capital will likely be used to expand the installation footprint, potentially beyond Italy and Switzerland, and to fund the research necessary to move from wellness claims toward more substantive clinical evidence.
The regulatory and evidence gap
For a health and bio correspondent, the most pressing question about Spherison is the nature of the evidence. The company’s website and materials describe offering "gentle and non-invasive hexaneural neurostimulation to reduce cortisol" for beauty and wellness centers [Spherison, Unknown]. A research paper suggests the immersive sound "may represent a feasible and well-tolerated nonpharmacological intervention for anxiety symptoms" [ResearchGate, Unknown]. The language of possibility and early research is appropriate, but it underscores the gap between a promising intervention and a validated therapeutic protocol.
The path to credibility, and perhaps to larger healthcare contracts, runs through structured clinical trials. Without peer-reviewed studies demonstrating efficacy for a specific condition, the technology risks being categorized as a wellness amenity rather than a clinical tool. The company’s current B2B spa and clinic channel is a prudent first step, but the ambition to address clinical anxiety will demand a higher standard of proof. The involvement of a figure like Faggin, with a lifetime of rigorous engineering behind him, suggests the team understands this burden. The next 12 months will show whether they can marshal resources to meet it.
The standard of care for anxiety
The patient population Spherison ultimately hopes to serve is vast: those living with anxiety disorders. Today, the first-line standard of care is a combination of pharmacotherapy, such as SSRIs, and psychotherapy, particularly cognitive behavioral therapy. For patients seeking non-pharmacological options, interventions like mindfulness-based stress reduction, biofeedback, or transcranial magnetic stimulation exist on a spectrum from accessible to highly specialized.
New entrants proposing audio-based neuromodulation enter a field where consumer wearables and meditation apps have already created a crowded, evidence-mixed marketplace. The differentiation for a company like Spherison must be its hardware's ability to create a specific, reproducible neurophysiological effect that outperforms a pair of headphones playing a guided meditation. Its future will be determined not by the prestige of its founders, but by whether it can demonstrate that its open-air sound field delivers a clinically meaningful benefit for patients, in a way that simpler, cheaper alternatives cannot.
Sources
- [Startupbusiness, October 2026] Spherison, a neuroscience start-up based on hexa-aural technology | https://www.startupbusiness.it/en/spherison-a-neuroscience-start-up-based-on-hexa-aural-technology/205879/
- [LinkedIn, Unknown] Spherison | LinkedIn | https://www.linkedin.com/company/spherison
- [ResearchGate, Unknown] Research paper on immersive natural sound stimulation for anxiety | https://www.researchgate.net/
- [Spherison, Unknown] Spherison company website | https://www.spherison.com/en/
- [Forbes, July 1997] Federico Faggin profile | https://www.forbes.com/forbes/1997/0707/6001312a.html
- [The New York Times, June 1990] Obituary referencing microprocessor invention | https://www.nytimes.com/1990/06/04/obituaries/an-inventor-of-the-microchip-robert-n-noyce-dies-at-62.html
- [Apple Podcasts, Unknown] Federico and Elvia Faggin Foundation podcast | https://podcasts.apple.com/
- [Startupbusiness, Unknown] Article referencing Alberto Baccari's role | https://www.startupbusiness.it/en/company/spherison/